BioSpace News Archive

MEI Pharma, Inc. and Kyowa Kirin Co., Ltd. announced that data from the zandelisib clinical development program, including the Phase 2 TIDAL study evaluating the intermittent dosing of zandelisib, an orally administered investigational phosphatidylinositol 3-kinase delta inhibitor in clinical development for the treatment of B-cell malignancies, is highlighted in a poster and an oral discussion session at the European Hematology Association 2022 Hybrid Congress.

MorphoSys AG is presenting data from multiple analyses of the ongoing MANIFEST study, an open-label Phase 2 clinical trial of pelabresib, an investigational BET inhibitor, in patients with myelofibrosis, a rare bone marrow cancer for which only limited treatment options are available.

J INTS BIO announced that it had conducted two Korean Advisory Board Meetings (ABM), first in December 2021 and the second in April this year for its novel orally administered 4th generation EGFR TKI ‘JIN-A02'.

ADC Therapeutics SA announced results from the ongoing pivotal Phase 2 clinical trial of camidanlumab tesirine in relapsed or refractory Hodgkin lymphoma.

Ryvu Therapeutics announced updated data from the ongoing Phase 1b dose-escalation study of RVU120 in patients with acute myeloid leukemia or high-risk myelodysplastic syndromes at the Annual European Hematology Association 2022 Hybrid Congress, June 9-17 in Vienna, Austria.

Data supports further development of CYT-338 in relapsed/refractory multiple myeloma.

Sparrow Pharmaceuticals, an emerging, clinical-stage biopharmaceutical company developing novel, targeted therapies to address unmet needs in both endocrinology and rheumatology, today announced that it will present new clinical pharmacology data at the Endocrine Society (ENDO) 2022 Annual Conference on its candidate, SPI-62, an HSD-1 inhibitor.

Wugen, Inc., a clinical-stage biotechnology company developing a pipeline of off-the-shelf cell therapies to treat a broad range of hematological and solid tumor malignancies, today presented new preclinical data demonstrating the enhanced anti-tumor properties of WU-NK-101, Wugen’s lead memory natural killer (NK) cell therapy product.

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new and updated results from the Phase 2 CAPTIVATE study evaluating IMBRUVICA ® (ibrutinib) in combination with venetoclax.

Zoetis to Participate in the Goldman Sachs 43rd Annual Global Healthcare Conference.